Leflunomide Treatment in Elderly Patients with Rheumatoid or Psoriatic Arthritis
Purchase on Springer.com
$49.95 / €39.95 / £34.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Disease-modifying antirheumatic drugs (DMARDs) play a crucial role in the treatment of persistent chronic synovitis, such as active rheumatoid arthritis (RA) and spondyloarthritis, by inducing or maintaining disease remission, reducing the frequency of flares or relapses, and allowing corticosteroids to be tapered while maintaining disease control.
The aim of this retrospective study was to evaluate the safety of, and adherence to treatment with, leflunomide in elderly RA and psoriatic arthritis patients compared with younger patients.
A total of 90 Italian patients (80 with active RA and 10 with psoriatic arthritis) were retrospectively examined at entry and after 24 months’ follow-up. Patients were divided into two groups according to age: those aged ≤65 years (n = 50) and those aged <65 years (n = 40). Each patient was analysed for clinical, demographic and laboratory parameters in order to evaluate liver, renal and haematological toxicity. Disease Activity Score including a 28-joint count (DAS28) and physician global assessment of disease activity (MD global) were measured to define disease activity.
During the 24-month follow-up period, 30 patients (33.3%) discontinued leflunomide: 17 patients (34.0%) in the group of patients aged ≤65 years and 13 patients (32.5%) in those aged <65 years. There were no differences in treatment withdrawal between the two groups. Overall, 10 patients (11.1%) in the entire study population discontinued leflunomide for lack of efficacy, while 21 (23.3%) discontinued the drug because of adverse effects (one patient withdrew because of both inefficacy and adverse effects). There were no significant differences in efficacy or adverse effects between patients aged ≤65 years and patients aged <65 years. There was also no significant difference in survival rates of leflunomide treatment when patients aged ≤65 years were compared with patients aged <65 years (p = 0.94).
There were no significant differences in withdrawal rates in the overall population when leflunomide monotherapy was compared with leflunomide combination therapy. There were also no significant differences in the types of adverse effects associated with monotherapy or combination therapy when the two age groups were compared.
Leflunomide is a useful and well tolerated DMARD for the treatment of RA and psoriatic arthritis in the elderly. The safety profile of, and adherence to, leflunomide is not different in older patients with chronic inflammatory joint diseases such as RA or psoriatic arthritis to that observed in younger patients.
Supplementary Material (0)
- American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002 Feb; 46(2): 328–46 CrossRef
- Sanders S, Harisdangkul V. Leflunomide for the treatment of rheumatoid arthritis and autoimmunity. Am J Med Sci 2002; 323: 190–3 CrossRef
- Cohen SB, Iqbal I. Leflunomide. Int J Clin Pract 2003; 57: 115–20
- Rozman B, Praprotnik S, Logar D, et al. Leflunomide and hypertension. Ann Rheum Dis 2002 Jun; 61(6): 567–9 CrossRef
- Rozman B. Clinical pharmacokinetics of leflunomide. Clin Pharmacokinet 2002; 41: 421–30 CrossRef
- Van Gestel AM, Prevoo ML, Van’t Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Arthritis Rheum 1996; 39: 34–40 CrossRef
- Sokka T, Hetland ML, Makinene H, et al. Remission and rheumatoid arthritis: data on patients receiving usual care 402 in twenty-four countries. Arthritis Rheum 2008 Sep; 58(9): 2642–51 CrossRef
- Ranganath VK, Furst DE. Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patient. Rheum Dis Clin North Am 2007; 33: 197–217 CrossRef
- Tutuncu A, Reed G, Kremer J, et al. Do patients with older onset rheumatoid arthritis receive less aggressive treatment? Ann Rheum Dis 2006; 65: 1226–9 CrossRef
- Schmajuk G, Schneeweiss S, Katz JN, et al. Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal. Arthritis Rheum 2007 Aug 15; 57(6): 928–34 CrossRef
- Cohen S, Cannon GW, Schiff M, et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Arthritis Rheum 2001; 44: 1984–92 CrossRef
- Kalden JR, Scott DL, Smolen JS, et al. Improved functional ability in patients with rheumatoid arthritis: long-term treatment with leflunomide versus sulfasalazine. J Rheumatol 2001; 28: 1983–91
- Kaltwasser JP. Leflunomide in psoriatic arthritis. Autoimmun Rev 2007; 6: 511–4 CrossRef
- Haibel H, Rudwaleit M, Braun J, et al. Six months open label trial of leflunomide in active ankylosing spondylitis. Ann Rheum Dis 2005 Jan; 64(1): 124–6 CrossRef
- Nurmohamed MT, van Halm VP, Dijkmans BA. Cardiovascular risk profile of antirheumatic agents in patients with osteoarthritis and rheumatoid arthritis. Drugs 2002; 62: 1599–609 CrossRef
- Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999; 22(159): 2542–50 CrossRef
- Ostchega Y, Dillon CF, Hughes JP, et al. Trends in hypertension prevalence, awareness, treatment, and control in older US adults: data from the National Health and Nutrition Examination Survey 1988 to 2004. J Am Geriatr Soc 2007; 55: 1056–65 CrossRef
About this Article
- Leflunomide Treatment in Elderly Patients with Rheumatoid or Psoriatic Arthritis
Drugs & Aging
Volume 26, Issue 5 , pp 395-402
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links